• 1
    Taylor DK, Neujahr D, Turka LA. Heterologous immunity and homeostatic proliferation as barriers to tolerance. Curr Opin Immunol 2004; 16: 558564.
  • 2
    Valujskikh A, Lakkis FG. In remembrance of things past: memory T cells and transplant rejection. Immunol Rev 2003; 196: 6574.
  • 3
    Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 2: 251262.
  • 4
    Chen Y, Heeger PS, Valujskikh A. In vivo helper functions of alloreactive memory CD4+ T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy. J Immunol 2004; 172: 54565466.
  • 5
    Kobayashi H, Koga S, Novick AC, Toma H, Fairchild RL. T-cell mediated induction of allogeneic endothelial cell chemokine expression. Transplantation 2003; 75: 529536.
  • 6
    Heeger PS, Greenspan NS, Kuhlenschmidt S et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163: 22672275.
  • 7
    Gebauer BS, Hricik DE, Atallah A et al. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2002; 2: 857866.
  • 8
    Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465474.
  • 9
    Adams AB, Williams MA, Jones TR et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 18871895.
  • 10
    Valujskikh A, Gomer A, Heeger PS. FTY720 induces prolonged allograft survival in the presence of memory CD4 T cells. Am J Transplant 2004; 4: 408.
  • 11
    Buhler LH, Spitzer TR, Sykes M et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 14051409.
  • 12
    Spitzer TR, Delmonico F, Tolkoff-Rubin N et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68: 480484.
  • 13
    Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 2002; 14: 592600.
  • 14
    Kirk AD. Crossing the bridge: large animal models in translational transplantation research. Immunol Rev 2003; 196: 176196.
  • 15
    London CA, Lodge MP, Abbas AK. Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol 2000; 164: 265272.
  • 16
    Zhai Y, Meng L, Gao F, Busuttil RW, Kupiec-Weglinski JW. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol 2002; 169: 46674673.
  • 17
    Valujskikh A, Pantenburg B, Heeger PS. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002; 2: 501509.
  • 18
    Adams AB, Pearson TC, Larsen CP. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 2003; 196: 147160.
  • 19
    Pantenburg B, Heinzel F, Das L, Heeger PS, Valujskikh A. T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol 2002; 169: 36863693.
  • 20
    Okazaki T, Iwai Y, Honjo T. New regulatory co-receptors: Inducible co-stimulator and PD-1. Curr Opin Immunol 2002; 14: 779782.
  • 21
    Ozkaynak E, Gao W, Shemmeri N et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001; 2: 591596.
  • 22
    Harada H, Salama AD, Sho M et al. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest 2003; 112: 234243.
  • 23
    Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003; 3: 609620.
  • 24
    Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 2003; 196: 85108.
  • 25
    Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001; 15: 445455.
  • 26
    Yuan X, Salama AD, Dong V et al. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol 2003; 170: 29492955.
  • 27
    Hintzen RQ, Lens SM, Lammers K, Kuiper H, Beckmann MP, Van Lier RA. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol 1995; 154: 26122623.
  • 28
    Yamada A, Salama AD, Sho M et al. CD70 Signaling is critical for CD28-independent CD8(+) T cell-mediated alloimmune responses in vivo. J Immunol 2005; 174: 13571364.
  • 29
    Wiethe C, Dittmar K Doan T, Lindenmaier W, Tindle R. Provision of 4–1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol 2003; 170: 29122922.
  • 30
    Foell JL, Diez-Mendiondo BI, Diez OH et al. Engagement of the CD137 (4–1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology 2004; 113: 8998.